Quick Answer
AN2 Therapeutics, Inc. reported Shares Outstanding of 27.41 million shares for fiscal year 2025.
AN2 Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 27.41M | -8.4% |
| 2024 | 29.92M | +0.6% |
| 2023 | 29.74M | +53.3% |
| 2022 | 19.40M | +610.6% |
| 2021 | 2.73M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 27.37M | -8.4% | -0.0% |
| June 30, 2025 | 27.38M | -8.2% | -9.2% |
| March 31, 2025 | 30.14M | +1.1% | +0.7% |
| December 31, 2024 | 29.92M | +0.6% | +0.2% |
| September 30, 2024 | 29.87M | +0.4% | +0.1% |
| June 30, 2024 | 29.83M | +36.0% | +0.0% |
| March 31, 2024 | 29.82M | +53.5% | +0.2% |
| December 31, 2023 | 29.74M | +53.3% | +0.0% |
- AN2 Therapeutics, Inc. showed a decrease of -8.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s shares outstanding has grown by 904.0% (from 2.73 million shares to 27.41 million shares).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: